Investment analysts at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Other research analysts also recently issued reports about the company. Canaccord Genuity Group cut their price target on Aptose Biosciences from $13.00 to $8.00 and set a “buy” rating for the company in a report on Monday, March 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Friday, March 24th.
Aptose Biosciences Stock Down 8.3 %
Aptose Biosciences stock opened at $0.55 on Monday. The firm has a market capitalization of $51.15 million, a PE ratio of -1.22 and a beta of 1.54. Aptose Biosciences has a 52 week low of $0.43 and a 52 week high of $1.43. The firm’s 50-day simple moving average is $0.63 and its 200 day simple moving average is $0.62.
Institutional Trading of Aptose Biosciences
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Toronto Dominion Bank lifted its stake in Aptose Biosciences by 80.4% during the third quarter. Toronto Dominion Bank now owns 43,851 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 19,541 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in Aptose Biosciences in the first quarter valued at approximately $27,000. Cetera Advisors LLC grew its holdings in shares of Aptose Biosciences by 40.1% during the fourth quarter. Cetera Advisors LLC now owns 86,827 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 24,847 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Aptose Biosciences by 3.6% during the 1st quarter. Renaissance Technologies LLC now owns 976,577 shares of the biotechnology company’s stock worth $1,328,000 after purchasing an additional 33,952 shares during the period. Finally, Sigma Planning Corp lifted its holdings in shares of Aptose Biosciences by 6.8% in the 3rd quarter. Sigma Planning Corp now owns 899,554 shares of the biotechnology company’s stock worth $535,000 after purchasing an additional 57,380 shares during the last quarter. 26.60% of the stock is owned by hedge funds and other institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Recommended Stories
- Get a free copy of the StockNews.com research report on Aptose Biosciences (APTO)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
